Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its blood cancer drug, Sarclisa (isatuximab) for the treatment of relapsed or refractory multiple myeloma (R/R MM) has met the co-primary endpoints.
Data from the study showed that the new SC formulation of Sarclisa in combination with Bristol Myers’ BMY Pomalyst (pomalidomide) and dexamethasone (Pd) when administered through an on-body delivery system (OBDS) demonstrated non-inferiority in objective response rate (ORR) and observed concentration before dosing (C trough) as compared to currently approved intravenous (IV) formulation of Sarclisa administered at a weight-based dose in combination with Pd in the given patient population.
ORR and C trough were the two co-primary endpoints of the IRAKLIA study. It is also the first phase III study to evaluate the SC administration of a cancer drug via an OBDS
Per the company, OBDS is a substitute delivery method planned to improve the patient experience and currently available SC administration.
In the past year, shares of SNY have declined 6.2% compared with the industry’s decrease of 2.2%.
Image Source: Zacks Investment Research
More on SNY's Sarclisa New SC formulation
The IRAKLIA study also met its key secondary endpoints where treatment with Sarclisa SC formulation demonstrated very good partial response, incidence rate of infusion reactions and C trough at cycle two compared to Sarclisa IV infusion.
Full data from the open-label IRAKLIA study will be presented at an upcoming medical conference.
Sarclisa SC formulation is currently being evaluated in various other studies across different combinations and lines of therapy.
The regulatory filing seeking approval for the Sarclisa SC formulation is expected to be submitted in the United States and Europe during the first half of 2025.
Approved Indications of SNY's Sarclisa IV
Sarclisa, in combination with Bristol Myers’ Pomalyst and dexamethasone, is approved to treat adult patients with MM who have received at least two prior therapies, including Revlimid and a proteasome inhibitor. The drug is also approved in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for treating patients with R/R MM who have received 1–3 prior lines of therapy. The drug is also approved for both these indications in the EU.
Both BMY’s Pomalyst and Revlimid are approved for multiple myeloma.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) in November 2024.
The CHMP’s positive opinion was based on data from the IMROZ phase III study. A final decision from the European Commission is expected shortly. The FDA had approved Sarclisa for a similar use in the United States in September 2024.
SNY's Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech sector are Puma Biotechnology, Inc. PBYI CytomX Therapeutics, Inc. CTMX, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares of PBYI have declined 22.2%.
PBYI’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.78%.
In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 55 cents to 35 cents for 2025. In the past year, shares of CTMX have surged 41.8%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
(We are reissuing this article to correct a mistake. The original article, issued on January 10, 2025, should no longer be relied upon.)
Free: 5 Stocks to Buy As Infrastructure Spending Soars
Trillions of dollars in Federal funds have been earmarked to repair and upgrade America’s infrastructure. In addition to roads and bridges, this flood of cash will pour into AI data centers, renewable energy sources and more.
In, you’ll discover 5 surprising stocks positioned to profit the most from the spending spree that’s just getting started in this space.
Download How to Profit from the Trillion-Dollar Infrastructure Boom absolutely free today.Sanofi (SNY) : Free Stock Analysis Report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
